Skip to main content

Table 2 Basic characteristics, risk factors for CAD and laboratory measurements

From: Long-term cardiac effects of modern treatment for Hodgkin’s lymphoma

 

AC + MRT (n = 132)

AC alone (n = 114)

Controls (n = 58)

p-value (ANOVA)

p-value AC + MRT vs. AC alone

p-value AC + MRT vs. controls

p-value AC alone vs. controls

Basic characteristics and risk factors

Age, years

46 ± 9

46 ± 10

47 ± 9

0.75

1.00

1.00

1.00

Males, n (%)

50 (37)

76 (65)

31 (53)

< 0.001

< 0.001

0.11

0.43

Body mass index, kg/m2

26.5 ± 5.3

26.6 ± 3.7

26.5 ± 4.9

1.00

1.00

1.00

1.00

Smoking (current or prior), n (%)

42 (31)

59 (50)

21 (36)

0.008

0.006

1.00

0.26

Systolic blood pressure, mmHg

131 ± 16

134 ± 17

134 ± 15

0.45

0.88

0.88

0.88

Diastolic blood pressure, mmHg

82 ± 11

84 ± 11

82 ± 9

0.51

1.00

1.00

0.79

High blood pressure, n (%)

56 (44)

48 (43)

21 (38)

0.70

1.00

1.00

1.00

 High measured BP

49 (38)

43 (38)

20 (36)

0.94

1.00

1.00

1.00

 Antihypertensive med.

23 (17)

16 (14)

4 (7)

0.20

1.00

0.23

0.66

High cholesterol, n (%)

39 (36)

46 (49)

19 (35)

0.11

0.16

1.00

0.30

 High measured chol.

28 (26)

40 (43)

20 (36)

0.048

0.044

0.58

1.00

 Lipid-lowering med.

15 (11)

11 (9)

0 (0)

0.034

1.00

0.029

0.16

Obesity, n (%)

26 (20)

24 (22)

12 (21)

0.93

1.00

1.00

1.00

Diabetes mellitus, n (%)

3 (2)

8 (7)

0 (0)

0.038

0.15

1.00

0.06

Established CAD, n (%)

9 (7)

4 (4)

1 (2)

0.22

0.64

0.34

1.00

 Prior myocardial inf.

5 (4)

4 (4)

0 (0)

0.34

1.00

0.48

0.62

Angina pectoris

6 (5)

4 (4)

1 (2)

0.61

1.00

0.97

1.00

Framingham risk score, % (IQR)

1.1 (0.4–3.4)

3.7 (0.8–11.9)

3.2 (1.0–8.0)

< 0.001

0.012

< 0.001

1.00

Cardioprotective medication, n (%)

28 (21)

21 (18)

4 (7)

0.06

1.00

0.06

0.20

Laboratory measurements

Total cholesterol, mmol/L

4.9 ± 0.9

5.0 ± 1.0

5.0 ± 0.8

0.43

1.00

0.65

1.00

Low density lipoprotein, mmol/L

3.1 ± 0.9

3.3 ± 1.0

3.2 ± 0.7

0.25

0.29

1.00

1.00

High density lipoprotein, mmol/L

1.5 ± 0.4

1.3 ± 0.4

1.4 ± 0.4

0.10

0.09

1.00

1.00

Triglycerides, mmol/L

1.3 ± 1.3

1.6 ± 1.1

1.3 ± 0.8

0.21

0.30

1.00

0.57

High-sensitive CRP, mg/L (IQR)

0.8 (0–3.6)

0.0 (0–1.7)

0.8 (0.8–2.1)

0.035

0.034

0.57

0.025

Pro-BNP, µmol/L (IQR)

70 (27–124)

< 50 (0–63)

< 50 (0–78)

< 0.001

< 0.001

< 0.001

0.81

HbA1c, %

36 ± 6

36 ± 8

34 ± 3

0.11

1.00

0.12

0.21

Creatinine,

70 ± 15

72 ± 12

65 ± 9

< 0.05

1.00

0.15

0.039

Hemoglobin, mg/dl

13.7 ± 1.2

14.3 ± 1.2

13.3 ± 0.8

< 0.001

< 0.001

0.41

< 0.001

  1. Data expressed as mean ± SD for parametric data and median (IQR) for non-parametric data. P-values derived from simple one-way ANOVA for continual, parametric data and Kruskal-Wallis one-way ANOVA for continual, non-parametric data. Comparison between individual groups performed with the Bonferonni correction for multiple comparisons. Framingham risk score is the 10-year risk of CAD calculated using the Framingham Risk Score for Hard Coronary Heart Disease. Cardioprotective medication is defined as using at least one of the following: ACE-inhibitors, ARBs, beta-blockers, statins or ASA